scoparianoside b has been researched along with streptonigrin in 2 studies
| Studies (scoparianoside b) | Trials (scoparianoside b) | Recent Studies (post-2010) (scoparianoside b) | Studies (streptonigrin) | Trials (streptonigrin) | Recent Studies (post-2010) (streptonigrin) |
|---|---|---|---|---|---|
| 5 | 0 | 4 | 399 | 7 | 48 |
| Protein | Taxonomy | scoparianoside b (IC50) | streptonigrin (IC50) |
|---|---|---|---|
| protein-arginine deiminase type-4 | Homo sapiens (human) | 2.5 | |
| Vif | Human immunodeficiency virus 1 | 10.82 | |
| Tat | Human immunodeficiency virus 1 | 42.129 | |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | 10.82 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 1.87 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 1.87 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 1.87 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 1.87 | |
| Sentrin-specific protease 6 | Homo sapiens (human) | 5.2 | |
| Sentrin-specific protease 2 | Homo sapiens (human) | 6.9 | |
| Sentrin-specific protease 1 | Homo sapiens (human) | 0.52 | |
| Protein-arginine deiminase type-3 | Homo sapiens (human) | 0.43 | |
| Protein-arginine deiminase type-4 | Homo sapiens (human) | 2.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hua, D; Wu, X | 1 |
| Gou, W; Guo, J; Hou, W; Li, Y; Liu, Q; Ning, H; Shang, H; Sun, X; Wei, H | 1 |
2 review(s) available for scoparianoside b and streptonigrin
| Article | Year |
|---|---|
Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases.
Topics: Humans; Neoplasms; Protein Processing, Post-Translational; Small Ubiquitin-Related Modifier Proteins; Sumoylation; Ubiquitin | 2022 |
Discovery of Natural Ursane-type SENP1 Inhibitors and the Platinum Resistance Reversal Activity Against Human Ovarian Cancer Cells: A Structure-Activity Relationship Study.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Female; Humans; Molecular Docking Simulation; Ovarian Neoplasms; Structure-Activity Relationship; Triterpenes | 2022 |